RxDoctor Payments Data

Joseph Simpson

Nurse Practitioner · Boardman, OHNPI 1568713055

Payments from drug & device makers

$932in general payments, 2019–2025

Across 36 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$574
  • Neurocrine Biosciences, Inc.$149
  • Acadia Pharmaceuticals Inc$116
  • Lilly USA, LLC$58
  • E.r. Squibb & Sons, L.L.C.$21
  • Novartis$14

What the payments were for

  • Food & beverage$932100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$932 in reported general payments places this provider in the 80th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$91,600
Medicare patients
154
Services billed
1,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$93,549
Austedo XrDeutetrabenazine20$52,631
TrulicityDulaglutide39$43,572
JardianceEmpagliflozin116$36,927
EliquisApixaban81$28,173
LokelmaSodium Zirconium Cyclosilicate22$16,259
RexultiBrexpiprazole16$11,384
FarxigaDapagliflozin Propanediol34$10,321
MovantikNaloxegol Oxalate46$10,231
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,573
XareltoRivaroxaban19$5,140
TradjentaLinagliptin19$5,000
Aripiprazole15$4,814
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$3,770
LantusInsulin Glargine,hum.Rec.Anlog48$3,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$149$93,54925 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$574$52,63120 claims
Lilly USA, LLCTrulicity$58$43,57239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Boardman

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →